An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction
暂无分享,去创建一个
Simone Brogi | Hajar Sirous | Giulia Chemi | Giuseppe Campiani | Simone Brogi | Giulia Chemi | G. Campiani | Hajar Sirous
[1] Pierre Tufféry,et al. The FAF-Drugs2 server: a multistep engine to prepare electronic chemical compound collections , 2011, Bioinform..
[2] P. Kollman,et al. Binding of a diverse set of ligands to avidin and streptavidin: an accurate quantitative prediction of their relative affinities by a combination of molecular mechanics and continuum solvent models. , 2000, Journal of medicinal chemistry.
[3] J. Canon,et al. Structure-based design of novel inhibitors of the MDM2-p53 interaction. , 2012, Journal of medicinal chemistry.
[4] Simone Brogi,et al. Targeting clinically-relevant metallo-β-lactamases: from high-throughput docking to broad-spectrum inhibitors , 2016, Journal of enzyme inhibition and medicinal chemistry.
[5] Olivier Sperandio,et al. FAF-Drugs2: Free ADME/tox filtering tool to assist drug discovery and chemical biology projects , 2008, BMC Bioinformatics.
[6] Niu Huang,et al. Physics-Based Scoring of Protein-Ligand Complexes: Enrichment of Known Inhibitors in Large-Scale Virtual Screening , 2006, J. Chem. Inf. Model..
[7] A. Levine,et al. The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.
[8] C. García-echeverría,et al. Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic. , 2013, Bioorganic & medicinal chemistry letters.
[9] M. Pinto,et al. Enhanced cytotoxicity of prenylated chalcone against tumour cells via disruption of the p53-MDM2 interaction. , 2015, Life sciences.
[10] Guoqiang Dong,et al. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction. , 2012, Journal of medicinal chemistry.
[11] M. Noble,et al. MDM2-p53 protein-protein interaction inhibitors: a-ring substituted isoindolinones. , 2011, Bioorganic & medicinal chemistry letters.
[12] Paul D Lyne,et al. Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. , 2006, Journal of medicinal chemistry.
[13] M. Tutone,et al. Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules. , 2010, Current medicinal chemistry.
[14] Stewart A. Adcock,et al. Molecular dynamics: survey of methods for simulating the activity of proteins. , 2006, Chemical reviews.
[15] Wenwei Hu,et al. Tumor suppressor p53: new functions of an old protein , 2011, Frontiers in Biology.
[16] Jonathan W. Essex,et al. A review of protein-small molecule docking methods , 2002, J. Comput. Aided Mol. Des..
[17] Shaomeng Wang,et al. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. , 2009, Annual review of pharmacology and toxicology.
[18] M. Coletta,et al. Development of Potent Inhibitors of the Mycobacterium tuberculosis Virulence Factor Zmp1 and Evaluation of Their Effect on Mycobacterial Survival inside Macrophages , 2018, ChemMedChem.
[19] S. Lowe,et al. Control of apoptosis by p53 , 2003, Oncogene.
[20] Abeer A. Alhadi,et al. PASS-assisted design, synthesis and antioxidant evaluation of new butylated hydroxytoluene derivatives. , 2014, European journal of medicinal chemistry.
[21] W. L. Jorgensen,et al. Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .
[22] Victor Guallar,et al. Importance of accurate charges in molecular docking: Quantum mechanical/molecular mechanical (QM/MM) approach , 2005, J. Comput. Chem..
[24] Anna Maria Almerico,et al. Molecular dynamics studies on Mdm2 complexes: an analysis of the inhibitor influence. , 2012, Biochemical and biophysical research communications.
[25] A. Levine,et al. Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.
[26] Xueliang Fang,et al. Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy. , 2006, Journal of medicinal chemistry.
[27] L. Vassilev,et al. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.
[28] F. Chibon,et al. Heterogeneous Mechanisms of Secondary Resistance and Clonal Selection in Sarcoma during Treatment with Nutlin , 2015, PloS one.
[29] A. Levine,et al. Surfing the p53 network , 2000, Nature.
[30] T. Darden,et al. A smooth particle mesh Ewald method , 1995 .
[31] Jonathan C. Fuller,et al. Predicting druggable binding sites at the protein-protein interface. , 2009, Drug discovery today.
[32] Jing Zhang,et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. , 2013, Journal of medicinal chemistry.
[33] Tingjun Hou,et al. Recent development and application of virtual screening in drug discovery: an overview. , 2004, Current pharmaceutical design.
[34] M. Hollstein,et al. p53 and human cancer: the first ten thousand mutations. , 2000, Advances in cancer research.
[35] A. Stegh. Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils , 2012, Expert opinion on therapeutic targets.
[36] Vladimir Poroikov,et al. Prediction of the Biological Activity Spectra of Organic Compounds Using the Pass Online Web Resource , 2014, Chemistry of Heterocyclic Compounds.
[37] L. Vassilev. p53 Activation by small molecules: application in oncology. , 2005, Journal of medicinal chemistry.
[38] Gabriele Cruciani,et al. Targeting the Conformational Transitions of MDM2 and MDMX: Insights into Dissimilarities and Similarities of p53 Recognition , 2008, J. Chem. Inf. Model..
[39] Simone Brogi,et al. Identification of novel fluorescent probes preventing PrPSc replication in prion diseases. , 2017, European journal of medicinal chemistry.
[40] Hoover,et al. Canonical dynamics: Equilibrium phase-space distributions. , 1985, Physical review. A, General physics.
[41] W. Im,et al. Novel pyrrolopyrimidine-based α-helix mimetics: cell-permeable inhibitors of protein−protein interactions. , 2011, Journal of the American Chemical Society.
[42] Woody Sherman,et al. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments , 2013, Journal of Computer-Aided Molecular Design.
[43] W. L. Jorgensen,et al. Comparison of simple potential functions for simulating liquid water , 1983 .
[44] V. Poroikov,et al. PASS-assisted exploration of new therapeutic potential of natural products , 2011, Medicinal Chemistry Research.
[45] Jeremy R. Greenwood,et al. Epik: a software program for pKa prediction and protonation state generation for drug-like molecules , 2007, J. Comput. Aided Mol. Des..
[46] Simone Brogi,et al. Computational Tool for Fast in silico Evaluation of hERG K+ Channel Affinity , 2017, Front. Chem..
[47] Josep Ramón Goñi,et al. Molecular dynamics simulations: advances and applications , 2015, Advances and applications in bioinformatics and chemistry : AABC.
[48] Simone Brogi,et al. Pharmacophore Modeling for Qualitative Prediction of Antiestrogenic Activity , 2009, J. Chem. Inf. Model..
[49] Hannah M Jones,et al. Predicting pharmacokinetic profiles using in silico derived parameters. , 2013, Molecular pharmaceutics.
[50] Maxwell D Cummings,et al. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. , 2005, Journal of medicinal chemistry.
[51] J. Miners,et al. Towards integrated ADME prediction: past, present and future directions for modelling metabolism by UDP-glucuronosyltransferases. , 2004, Journal of molecular graphics & modelling.
[52] Zeger Debyser,et al. Synthesis, Molecular Modelling and Biological Studies of 3-hydroxy-pyrane-4-one and 3-hydroxy-pyridine-4-one Derivatives as HIV-1 Integrase Inhibitors. , 2019, Medicinal chemistry (Shariqah (United Arab Emirates)).
[53] D. Bernard,et al. Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment , 2014, Journal of medicinal chemistry.
[54] A. Palmeira,et al. Medicinal Chemistry Strategies to Disrupt the p53–MDM2/MDMX Interaction , 2016, Medicinal research reviews.
[55] Markus J. Bauer,et al. Discovery of Novel Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one Compounds as Chemically Stable and Orally Active Inhibitors of the MDM2-p53 Interaction. , 2016, Journal of medicinal chemistry.
[56] B. Berne,et al. A Multiple-Time-Step Molecular Dynamics Algorithm for Macromolecules , 1994 .
[57] G J Williams,et al. The Protein Data Bank: a computer-based archival file for macromolecular structures. , 1978, Archives of biochemistry and biophysics.
[58] P. Charifson,et al. Are free energy calculations useful in practice? A comparison with rapid scoring functions for the p38 MAP kinase protein system. , 2001, Journal of medicinal chemistry.
[59] Federico D. Sacerdoti,et al. Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters , 2006, ACM/IEEE SC 2006 Conference (SC'06).
[60] J. Deschamps,et al. Structure-based design of potent non-peptide MDM2 inhibitors. , 2005, Journal of the American Chemical Society.
[61] Gang Fu,et al. PubChem Substance and Compound databases , 2015, Nucleic Acids Res..
[62] Sharmila Patel,et al. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer , 2008, Expert opinion on investigational drugs.
[63] A. Levine,et al. Functions of the MDM2 oncoprotein , 1999, Cellular and Molecular Life Sciences CMLS.
[64] S. Parasuraman. Prediction of activity spectra for substances , 2011, Journal of pharmacology & pharmacotherapeutics.
[65] Matthew P. Repasky,et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.
[66] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .
[67] M. Klein,et al. Constant pressure molecular dynamics algorithms , 1994 .
[68] Simone Brogi,et al. Structure-based discovery of the first non-covalent inhibitors of Leishmania major tryparedoxin peroxidase by high throughput docking , 2015, Scientific Reports.
[69] Jacob D. Durrant,et al. Molecular dynamics simulations and drug discovery , 2011, BMC Biology.
[70] A. Palmeira,et al. Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach. , 2013, Biochemical pharmacology.
[71] Simone Brogi,et al. 3D-QSAR using pharmacophore-based alignment and virtual screening for discovery of novel MCF-7 cell line inhibitors. , 2013, European journal of medicinal chemistry.
[72] Matthew P. Repasky,et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.
[73] Garrett M Morris,et al. Assessing the role of polarization in docking. , 2008, The journal of physical chemistry. A.
[74] P. Chène. Inhibiting the p53–MDM2 interaction: an important target for cancer therapy , 2003, Nature Reviews Cancer.